DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
About
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes. This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the propose.
The DoW Amyotrophic Lateral Sclerosis Research Program Clinical Outcomes and Biomarkers Award (COBA) is a federal research funding opportunity designed for organizations and research teams focused on advancing ALS treatment development and patient care. This grant supports the critical work of developing and validating clinical outcomes measures and biomarkers that can enrich clinical trials for amyotrophic lateral sclerosis. Researchers and entrepreneurs in the biotech, medical device, and digital health sectors should consider applying if they are working on identifying, developing, or validating biomarkers—including susceptibility, diagnostic, monitoring, prognostic, predictive, response, or safety biomarkers. The program also funds the development of clinician-reported, observer-reported, patient-reported, and performance-based outcome measures for ALS. Projects can be tailored to specific therapies, therapeutic classes, or ALS subtypes (such as particular genetic mutations), rather than requiring broad applicability across all patient populations. Notably, applicants are encouraged to incorporate digital health innovations such as wearable devices, smartphone sensors, video or voice recordings, and imaging studies. Community collaboration is a key requirement, making this ideal for organizations that can demonstrate meaningful engagement with ALS patient communities and stakeholders throughout the research process.
Funding Facts
● Applications openDeadline
September 30, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Not specified
Deadline
2026-09-30
Grant Type
federal
Application Cycle
Annual
Best For
ALS research organizations, biotech companies, digital health innovators, academic medical centers, and clinical trial researchers developing biomarkers and outcome measures
Frequently Asked Questions
Who is eligible for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?
Specific eligibility criteria are not provided in the available information. Applicants should visit the official Department of Defense grant website or the official ALSRP program page for complete eligibility requirements, institutional affiliations, and qualification details for FY26 applications.
How much funding does DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award provide?
The specific funding amount is not specified in the available program information. Funding may vary by cycle and project scope. Please consult the official program announcement or the DoD grant management website for current FY26 funding details and award ranges.
How do I apply for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?
Applications are typically submitted through the official DoD grants portal or Grants.gov. The application deadline for this FY26 program is September 30, 2026. Applicants should review the full program announcement on the official DoD or ALSRP website for detailed submission instructions, required documentation, and specific application procedures.
What can DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award funding be used for?
This award supports the development and validation of clinical outcomes measures and biomarkers for ALS research. Eligible projects include identifying and validating biomarkers (such as diagnostic, monitoring, prognostic, predictive, and safety biomarkers), developing clinical outcome measures, optimizing existing outcome measures, and incorporating digital health technologies like wearable devices, smartphone sensors, video/voice recordings, and imaging studies. Projects must include community collaboration with ALS stakeholders and can be tailored to specific therapies or ALS subtypes rather than requiring broad applicability.
Last updated: July 5, 2026